Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance

Cancer Prevention Research

Volumn 7, Issue 7, 2014, Pages 766-776

  Moreel, Xavier ^a,b   Allaire, Janie ^a,b   Léger, Caroline ^a,b   Caron, André ^a,b   Labonté, Marie Ève ^c   Lamarche, Benoît ^c   Julien, Pierre ^b   Desmeules, Patrice ^a,b   Têtu, Bernard ^a,b   Fradet, Vincent ^a,b,c  

^a LAVAL UNIVERSITY   (Canada)

^b Université Laval   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; FAT INTAKE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PREVENTION; CLINICAL ARTICLE; DIETARY INTAKE; DISEASE SURVEILLANCE; ERYTHROCYTE; FAT INTAKE; FOOD FREQUENCY QUESTIONNAIRE; GLEASON SCORE; HUMAN; HUMAN TISSUE; LOW RISK PATIENT; MALE; OBSERVATION; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; RISK REDUCTION; TISSUES; ADMINISTRATION AND DOSAGE; CANCER STAGING; DISEASE COURSE; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROSPECTIVE STUDY; PROSTATE TUMOR;

AGED; CLINICAL TRIALS, PHASE II AS TOPIC; DIETARY FATS; DISEASE PROGRESSION; ERYTHROCYTES; FATTY ACIDS, OMEGA-3; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84904289668     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0349     Document Type: Article

References (49)

1. Hamid AR, Umbas R, Mochtar CA. Recent role of inflammation in prostate diseases: chemoprevention development opportunity. Acta Med Indones 2011;43:59-65.
2. Wendel M, Heller AR. Anticancer actions of omega-3 fatty acids-current state and future perspectives. Anticancer Agents Med Chem 2009;9:457-70.
3. Ratnayake WM, Galli C. Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper. Ann Nutr Metab 2009;55:8-43.
4. Reese AC, Fradet V, Witte JS. Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer. J Nutrigenet Nutrigenomics 2009;2:149-58.
5. Chan JM, Weinberg V, Magbanua MJ, Sosa E, Simko J, Shinohara K, et al. Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. Cancer Causes Control 2011;22:141-50.
6. Magbanua MJ, Roy R, Sosa EV, Weinberg V, Federman S, Mattie MD, et al. Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation. PLoS ONE 2011;6:e24004.
7. Terry P, Lichtenstein P, Feychting M, Ahlbom A, Wolk A. Fatty fish consumption and risk of prostate cancer. Lancet 2001;357:1764-6. (Pubitemid 32524210)
8. Augustsson K, Michaud DS, Rimm EB, Leitzmann MF, Stampfer MJ, Willett WC, et al. A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:64-7. (Pubitemid 36110160)
9. Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC, et al. Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr 2004;80:204-16.
10. Williams CD, Whitley BM, Hoyo C, Grant DJ, Iraggi JD, Newman KA, et al. A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. Nutr Res 2011;31:1-8.
11. Norrish AE, Skeaff CM, Arribas GL, Sharpe SJ, Jackson RT. Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br J Cancer 1999;81:1238-42.
12. Terry PD, Rohan TE, Wolk A. Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a reviewof the epidemiologic evidence. Am J Clin Nutr 2003;77:532-43. (Pubitemid 36258559)
13. Brasky TM, Till C, White E, Neuhouser ML, Song X, Goodman P, et al. Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol 2011;173:1429-39.
14. Sala-Vila A, Calder PC. Update on the relationship of fish intake with prostate, breast, and colorectal cancers. Crit Rev Food Sci Nutr 2011;51:855-71.
15. Dahm CC, Gorst-Rasmussen A, Crowe FL, Roswall N, Tjonneland A, Drogan D, et al. Fatty acid patterns and risk of prostate cancer in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2012;96:1354-61.
16. Chua ME, Sio MC, Sorongon MC, Dy JS. Relationship of dietary intake of omega-3 and omega-6 Fatty acids with risk of prostate cancer development: a meta-analysis of prospective studies and review of literature. Prostate Cancer 2012;2012:826254.
17. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101. (Pubitemid 40617061)
18. Torfadottir JE, Valdimarsdottir UA, Mucci LA, Kasperzyk JL, Fall K, Tryggvadottir L, et al. Consumption of fish products across the lifespan and prostate cancer risk. PloS ONE 2013;8:e59799.
19. Pelser C, Mondul AM, Hollenbeck AR, Park Y. Dietary fat, fatty acids, and risk of prostate cancer in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev 2013;22:697-707.
20. Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, et al. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst 2013;105:1132-41.
21. Shannon J, O'Malley J, Mori M, Garzotto M, Palma AJ, King IB. Erythrocyte fatty acids and prostate cancer risk: a comparison of methods. Prostaglandins Leukot Essent Fatty Acids 2010;83:161-9.
22. Park SY, Wilkens LR, Henning SM, Le Marchand L, Gao K, Goodman MT, et al. Circulating fatty acids and prostate cancer risk in a nested case-control study: the Multiethnic Cohort. Cancer Causes Control 2009;20:211-23.
23. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46:488-94.
24. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123-31.
25. Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet 2012;379:1103-11.
26. Payton S. Prostate cancer: Third time lucky? Dutasteride for tertiary prevention of prostate cancer. Nat Rev Urol 2013;10:63.
27. Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012;62:976-83.
28. Labonte ME, Cyr A, Baril-Gravel L, Royer MM, Lamarche B. Validity and reproducibility of a web-based, self-administered food frequency questionnaire. Eur J Clin Nutr 2012;66:166-73.
29. Lohman T, Roche A, Martorell R. Anthropometric standardization reference manual. Champaign, IL: Human Kinetics Books; 1988.
30. Schakel SF, Sievert YA, Buzzard IM. Sources of data for developing and maintaining a nutrient database. J Am Diet Assoc 1988;88:1268-71.
31. Canada S. Canadian Nutrient File. 2007 [cited 2007; Available from: www.healthcanada.gc.ca/cnf.
32. Wang Y, Crawford MA, Chen J, Li J, Ghebremeskel K, Campbell TC, et al. Fish consumption, blood docosahexaenoic acid and chronic diseases in Chinese rural populations. Comp Biochem Physiol A Mol Integr Physiol 2003;136:127-40. (Pubitemid 37289412)
33. Rudkowska I, Paradis AM, Thifault E, Julien P, Tchernof A, Couture P, et al. Transcriptomic and metabolomic signatures of an n-3 polyunsaturated fatty acids supplementation in a normolipidemic/normocholesterolemic Caucasian population. J Nutr Biochem 2013;24:54-61.
34. Shaikh NA, Downar E. Time course of changes in porcine myocardial phospholipid levels during ischemia. A reassessment of the lysolipid hypothesis. Circ Res 1981;49:316-25. (Pubitemid 11053292)
35. Lepage G, Roy CC. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 1986;27:114-20. (Pubitemid 16045295)
36. Poppitt SD, Kilmartin P, Butler P, Keogh GF. Assessment of erythrocyte phospholipid fatty acid composition as a biomarker for dietary MUFA, PUFA or saturated fatty acid intake in a controlled cross-over intervention trial. Lipids Health Dis 2005;4:30.
37. Fligner MA, Policello GE. Robust Rank Procedures for the Behrens-Fisher Problem. J Am Stat Assoc 1981;76:162-8.
38. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol 2011;29:2795-800.
39. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007;121:1571-8. (Pubitemid 47328718)
40. Rise P, Eligini S, Ghezzi S, Colli S, Galli C. Fatty acid composition of plasma, blood cells and whole blood: relevance for the assessment of the fatty acid status in humans. Prostaglandins Leukot Essent Fatty Acids 2007;76:363-9. (Pubitemid 47095278)
41. Aronson WJ, Kobayashi N, Barnard RJ, Henning S, Huang M, Jardack PM, et al. Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer Prev Res 2011;4:2062-71.
42. Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MT IV, et al. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev 2008;17:3577-87.
43. Dougherty RM, Galli C, Ferro-Luzzi A, Iacono JM. Lipid and phospholipid fatty acid composition of plasma, red blood cells, and platelets and how they are affected by dietary lipids: a study of normal subjects from Italy, Finland, and the USA. Am J Clin Nutr 1987;45:443-55. (Pubitemid 17020812)
44. Chua ME, Sio MC, Sorongon MC, Morales ML Jr. The relevance of serum levels of long chain omega-3 polyunsaturated fatty acids and prostate cancer risk: a meta-analysis. Canadian Urol Assoc J 2013;7:E333-43.
45. Mozaffarian D, Wu JH. (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr 2012;142:614S-25S.
46. Fritz V, Benfodda Z, Rodier G, Henriquet C, Iborra F, Avances C, et al. Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther 2010;9:1740-54.
47. Aronson WJ, Barnard RJ, Freedland SJ, Henning S, Elashoff D, Jardack PM, et al. Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol 2010;183:345-50.
48. Avery KN, Donovan JL, Gilbert R, Davis M, Emmett P, Down L, et al. Men with prostate cancer make positive dietary changes following diagnosis and treatment. Cancer Causes Control 2013;24:1119-28.
49. Graefen M, Schlomm T. From diagnostic tool to disease monitoring: the growing role of prostate biopsies. Eur Urol 2013;63:231-3.